<DOC>
	<DOC>NCT02786979</DOC>
	<brief_summary>The objective was to evaluate the efficacy and safety of combination of beraprost and aspirin for prevention of arteriosclerosis progress in type 2 diabetes mellitus patients.</brief_summary>
	<brief_title>Efficacy and Safety of Dorner Tablets and Aspirin for Prevention of Arteriosclerosis Progress in Type 2 Diabetes Mellitus Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Arteriosclerosis</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Beraprost</mesh_term>
	<mesh_term>Epoprostenol</mesh_term>
	<criteria>Patients diagnosed as type 2 diabetes mellitus; Patients who had the intimamedia thickness (IMT) of carotid artery â‰¥1.1 mm in at least one side; Patients who had results of aspartate aminotransferase, alanine aminotransferase, and serum creatinine no more than 1.5 times higher than the upper limit of normal; Patients who had not cardio or cerebral vascular events within 3 months, including nonfatal myocardial infarction, stable and unstable angina pectoris, and nonfatal cerebral ischemic and hemorrhagic stroke; Patients who had their systolic blood pressure &lt;160 mmHg, diastolic blood pressure &lt;100 mmHg, and glycated hemoglobin (HbA1c) &lt;8.0%; Patients who had not taken any medications with antithrombotic and antiplatelet effect within 3 months; Patients who had peptic ulcer or active alimentary tract hemorrhage; Patients who had a known allergy to prostacycline or nonsteroid medications; Patients who were pregnant, breast feeding, or had planned to be pregnant; Patients who were attending or had attended any clinical studies within 3 months;</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Type 2 Diabetes Mellitus</keyword>
	<keyword>Arteriosclerosis</keyword>
	<keyword>beraprost</keyword>
	<keyword>Aspirin</keyword>
</DOC>